This study is testing a new treatment called STK-012 for people with certain types of advanced solid tumors, which are abnormal growths of cells that can turn into cancer. The study has two parts: the first part (Phase 1a) is to find out how much STK-012 is safe to use alone or with other cancer treatments. The second part (Phase 1b) checks how well STK-012 works at a dose they think is best when used alone or with other treatments.

The study is open to people who have already tried standard treatments but did not get better, or who cannot take such treatments. Some participants will get STK-012 with other drugs like pembrolizumab (a medicine that helps the immune system fight cancer), pemetrexed, and carboplatin (both are chemotherapy drugs).

• The study is conducted at multiple centers, meaning you might have to travel for participation.
• You cannot participate if you've had certain treatments recently, like other cancer therapies or radiotherapy.
• The study aims to find the safe dose and see how well the treatment works.